Comparing the effects of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome (OHSS) in PCOS patients undergoing infertility treatment.

Comparing the effects of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome in Polycystic ovary syndrome patients undergoing infertility treatment.

The studied sample is among infertile women who are candidates for assisted reproductive techniques referring to Arash Hospital, who will be selected based on the entry criteria and will be divided into two intervention groups using the random allocation method. We designed this study as a pilot with 20 people in each group.

This study will be conducted as a clinical trial. In this study, 40 pregnant women candidates for assisted reproductive techniques referred to Arash Hospital will be selected and randomly divided into cabergoline group and hydroxychloroquine group. The study will be conducted in a triple blind manner and the patients, the evaluating doctor and the statistical analyst will not know about the allocation of people to the intervention and control groups.

Inclusion criteria: Having polycystic ovary syndrome according to the Rotterdam criteria Age 18 to 40 years Number of antral follicles (AFC) above 20 AMH>3.36 ng/ml BMI <30 kg/m2 Exit criteria: Suffering from endometriosis Decreased ovarian reserve Chromosomal abnormalities History of sensitivity to drugs that inhibit dopamine or cabergoline Also, patients who do not take the desired drugs on a daily basis and those who have allergic symptoms or drug side effects will be excluded from the study.

The examined samples will be selected based on the inclusion criteria and will be randomly divided into cabergoline and hydroxychloroquine groups. Both groups are under ART with antagonist cycle.

Incidence of Ovarian Hyperstimulation Syndrome as the primary and blood levels of urea, creatinine, sodium and potassium as secondary outcomes.

Randomization method: simple randomization In this method, we use simple randomization models such as the use of a table of random numbers or the use of computer randomization methods, and we place each client in the intervention or control group. One of the advantages of this type of randomization is that the type of treatment assigned to the two groups is completely unpredictable and according to the probability theory, it can be guaranteed that in a large number, the sample size of the study will be the same in the intervention and control groups. Also, the implementation of this method is very simple.

The study will be conducted in a triple blind study and the patients, the evaluating doctor and the statistical analyst will not know about the allocation of people to the intervention and control groups. In a triple blind study, the participant, the researcher, and the statistical consultant are all unaware of the arrangement of the groups. The way to conduct triple-blind studies is that there is an external observer in this studies who assigns common names such as: A and B to the drug (intervention) and placebo (control).

Part of the data, such as information related to the main outcome or similar, can be shared

The access period starts 6 months after the results are published

Researchers working in academic and scientific institutions

Since the data related to patients is confidential, under the conditions that a person has a study in line with us and by maintaining the confidentiality of the data, she/he can request the use of the data.

Dr. Elnaz Salari Address: Resalat Highway, after Shahid Bagheri Highway, Shahid Bagh Darnia St. (Rashid Shamali), corner of 162 Alley (Shahid Abdul Majid), Arash Women's General Hospital Postal code 16539115981 Phone 02177883283

.After the request, if the executors and the sponsor agree to the request, the documents will be provided to the requester after about 3 months.